Roth Capital lowered the firm's price target on Beauty Health to $2 from $2.50 and keeps a Buy rating on the shares. The firm is updating its model after the company's Q1 results while noting that Beauty Health continues to face competitive pressures particularly in the lower end of the market where knock-offs and scaled-down models suffice for cost-sensitive providers, the analyst tells investors in a research note.
